Who will enroll? Predicting participation in a phase II aids vaccine trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 3, 2001, Pages 281-288

  Halpern, Scott D ^a,c   Metzger, David S ^a   Berlin, Jesse A ^a   Ubel, Peter A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Center for Clinical Epidemiology and Biostatistics   (United States)

Author keywords

Ethics; Human experimentation; Human volunteers; Informed consent; Patient recruitment; Research design; Vaccine

Indexed keywords

ALVAC VCP205; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; MAJOR CLINICAL STUDY; MEDICAL ETHICS; MOTIVATION; PATIENT COMPLIANCE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VOLUNTEER;

EID: 0035394562     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200107010-00011     Document Type: Article

References (35)

1. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: Survey of 71 "negative" trials
2. Statistics and ethics in medical research III: How large a sample?
3. Some adaptive strategies for inadequate sample acquisition in Veterans Administration cooperative clinical trials
4. Randomization designs in comparative clinical trials
5. Recruitment experience in clinical trials: Literature summary and annotated bibliography
6. Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators
7. Scientific value and validity as ethical requirements for research: A proposed explication
8. The ethical design of human experiments
9. What makes clinical research ethical?
10. HIV preventive vaccine efficacy trials in the United States: An overview of target communities' concerns
11. Participation of homosexual/bisexual men in preventive HIV vaccine trials: Baseline attitudes and concerns and predicted behaviors during trials
12. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?
13. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men
14. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE
15. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand
16. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials
17. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand
18. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
19. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study
20. The meaning and use of the area under a receiver operating characteristic (ROC) curve
21. Patients' preferences and randomised trials
22. Are randomized controlled trials controlled? Patient preferences and unblind trials
23. Patients' willingness to enter clinical trials: Measuring the association with perceived benefit and preference for decision participation
24. Predicting Utility
25. Understanding patients' decisions: Cognitive and emotional perspectives
26. Wouldn't it be nice? Predicting future feelings
27. Do patients' evaluations of a future health state change when they actually enter that state?
28. Ethical considerations in randomized controlled clinical trials
29. Abandoning informed consent
30. The context of consent
31. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial
32. Informed consent for HIV testing in a South African hospital: Is it truly informed and truly voluntary?